Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Metabolism & Endocrine
Filter     Order     Display # 
Date Item Title
06 Aug 2008 Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
05 Aug 2008 Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis...
04 Aug 2008 Karo Bio Announces Successful Phase II Study with Eprotirome in Combination with Statin
04 Aug 2008 Theratechnologies Reports on Positive Body Image Parameters at the International AIDS Conference
04 Aug 2008 Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
03 Aug 2008 MDRNA Announces Phase 2 Trial of PYY(3-36) Does not Meet Weight Loss Endpoint
31 Jul 2008 AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
29 Jul 2008 SemBioSys submits IND for safflower-produced insulin to U.S. FDA
28 Jul 2008 Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
26 Jul 2008 Once-yearly Aclasta(R) recommended in EU to treat male osteoporosis and reduce risk of new fractures in patients after hip fracture
24 Jul 2008 Zelos Therapeutics Reaches Agreement with the FDA and EMEA for a Registration Study of ZT-031 for the Treatment of Osteoporosis
24 Jul 2008 Biodel Announces Publications Demonstrating Superior Metabolic Profile of VIAject(TM) Compared to the Rapid-acting Analog Humalog(R) and Regular Human Insulin in Healthy Volunteers and Compared to Regular Human Insulin in Patients with Type 1 Diabetes
23 Jul 2008 Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes
23 Jul 2008 Merck & Co., Inc. (MRK)'s JANUMET (TM) Approved in the European Union for Treatment of Type 2 Diabetes
22 Jul 2008 Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia
19 Jul 2008 Galapagos announces first milestone in osteoporosis collaboration with Lilly
17 Jul 2008 Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
16 Jul 2008 Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX(TM) (HE3286) in Type-2 Diabetes Patients; Expands Sites to Accelerate Enrollment
15 Jul 2008 Novo Nordisk files for regulatory approval of liraglutide in Japan
14 Jul 2008 Penwest Begins Phase Ia Clinical Trial of A0001, a Compound For Treatment of Mitochondrial Diseases
14 Jul 2008 DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes
14 Jul 2008 Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
13 Jul 2008 Merck Sharp & Dohme (MRK) TREDAPTIVE(TM) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides
09 Jul 2008 Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
09 Jul 2008 Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
08 Jul 2008 Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
02 Jul 2008 MicroIslet Provides Safety and Efficacy Data Update
01 Jul 2008 Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
30 Jun 2008 Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
26 Jun 2008 Andromeda Biotech Announces Successful Interim Results of Leading Product DiaPep 227 for Treatment of Type 1 Diabetes Phase III clinical study with DiaPep 277 will continue as planned following the Interim Analysis of Data demonstrating Safety and Efficac
25 Jun 2008 Osiris Therapeutics Announces $2 Million Milestone Payment for Clinical Progress of a Stem Cell Therapy for Type 1 Diabetes
24 Jun 2008 Novo Nordisk receives approval in the US for PrandiMet(TM)
23 Jun 2008 Emisphere Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonists for Diabetes
22 Jun 2008 Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)
19 Jun 2008 OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602
19 Jun 2008 Metabasis Announces Promising Results from Its Phase 1b Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
18 Jun 2008 Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide
18 Jun 2008 Theratechnologies Reports Positive 26-Week REsults Fro its Second Tesamorelin Phase 3 Trial
17 Jun 2008 AstraZeneca and Columbia University Medical Center Sign Strategic Research Collaboration to Develop Novel Therapeutics for Diabetes and Obesity
17 Jun 2008 Akesis Pharmaceuticals Reports Positive Results from its Phase IIa Trial of AKP-020 for Type 2 Diabetes
16 Jun 2008 Significant weight loss sustained in obese people treated with liraglutide for one year
16 Jun 2008 Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 fro Treatment of Dyslipidemia
16 Jun 2008 Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting
15 Jun 2008 AMT prepares for submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
12 Jun 2008 Lilly and TransPharma Medical Announce Licensing and Development Agreement
10 Jun 2008 Roche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials
10 Jun 2008 Acomplia (rimonabant) significantly improved glucose control in type 2 diabetes patients treated with insulin
10 Jun 2008 AtheroGenics Reports Clinical Data on Novel Anti-Inflammatory Anti-Oxidant Agent, AGI-1067, at American Diabetes Association Annual Meeting
10 Jun 2008 Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting
10 Jun 2008 Qnexa Reduces Hemoglobin A1c by 1.2 Percent in 28 Weeks
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 101 - 150 of 1041

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics